Abstract
The management of patients affected by epidemolysis bullosa requires an integrated approach involving different specialties. A cornerstone of clinical management is the prevention and treatment of mechanobullous ulcerations of the patient's skin, which significantly impact the quality of life and can be the cause of septic and neoplatic complications. This article describes the preliminary clinical evaluation of the use of allogeneic cord blood platelet gel, a novel blood component obtained from umbilical cord blood of healthy, term neonates, for the treatment of skin ulcers in patients with dystrophic epidermolysis bullosa. The promising clinical results obtained in this small patient group support the development of larger controlled clinical trials to compare the efficacy of platelet gel obtained from cord blood versus traditional platelet gel prepared from adult blood donors and versus current standard approaches of wound care in these patients.
| Original language | English |
|---|---|
| Pages (from-to) | 370-373 |
| Journal | Transfusion and Apheresis Science |
| Volume | 57 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2018 |
Fingerprint
Keywords
- Epidermolysis bullosa
- Platelet gel
- Umbilical cord blood
ASJC Scopus subject areas
- Hematology
Cite this
Cord blood platelet gel for the treatment of inherited epidermolysis bullosa. / Gelmetti, Alessandra; Greppi, Noemi; Guez, Sophie; Grassi, Francesca; Rebulla, Paolo; Tadini, Gianluca.
In: Transfusion and Apheresis Science, Vol. 57, No. 3, 2018, p. 370-373.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cord blood platelet gel for the treatment of inherited epidermolysis bullosa
AU - Gelmetti, Alessandra
AU - Greppi, Noemi
AU - Guez, Sophie
AU - Grassi, Francesca
AU - Rebulla, Paolo
AU - Tadini, Gianluca
PY - 2018
Y1 - 2018
N2 - The management of patients affected by epidemolysis bullosa requires an integrated approach involving different specialties. A cornerstone of clinical management is the prevention and treatment of mechanobullous ulcerations of the patient's skin, which significantly impact the quality of life and can be the cause of septic and neoplatic complications. This article describes the preliminary clinical evaluation of the use of allogeneic cord blood platelet gel, a novel blood component obtained from umbilical cord blood of healthy, term neonates, for the treatment of skin ulcers in patients with dystrophic epidermolysis bullosa. The promising clinical results obtained in this small patient group support the development of larger controlled clinical trials to compare the efficacy of platelet gel obtained from cord blood versus traditional platelet gel prepared from adult blood donors and versus current standard approaches of wound care in these patients.
AB - The management of patients affected by epidemolysis bullosa requires an integrated approach involving different specialties. A cornerstone of clinical management is the prevention and treatment of mechanobullous ulcerations of the patient's skin, which significantly impact the quality of life and can be the cause of septic and neoplatic complications. This article describes the preliminary clinical evaluation of the use of allogeneic cord blood platelet gel, a novel blood component obtained from umbilical cord blood of healthy, term neonates, for the treatment of skin ulcers in patients with dystrophic epidermolysis bullosa. The promising clinical results obtained in this small patient group support the development of larger controlled clinical trials to compare the efficacy of platelet gel obtained from cord blood versus traditional platelet gel prepared from adult blood donors and versus current standard approaches of wound care in these patients.
KW - Epidermolysis bullosa
KW - Platelet gel
KW - Umbilical cord blood
UR - http://www.scopus.com/inward/record.url?scp=85048833620&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048833620&partnerID=8YFLogxK
U2 - 10.1016/j.transci.2018.05.021
DO - 10.1016/j.transci.2018.05.021
M3 - Article
VL - 57
SP - 370
EP - 373
JO - Transfusion and Apheresis Science
JF - Transfusion and Apheresis Science
SN - 1473-0502
IS - 3
ER -